You are viewing the site in preview mode

Skip to main content
Fig. 3 | Health Economics Review

Fig. 3

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

Fig. 3

a Probabilistic sensitivity analysis of the incremental cost-effectiveness ratio of Apixaban compared with warfarin. b Acceptability curve for Apixaban compared with warfarin. a Upper threshold per QALY gained: 34664 USD; Lower Threshold per QALY gained: 11558 USD. b Probability of being accepted as a cost-effectiveness alternative considering the upper and lower thresholds showed in figure 3a

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us